Confirmed: Cemiplimab Ups Survival in Recurrent Cervical Cancer Confirmed: Cemiplimab Ups Survival in Recurrent Cervical Cancer

Just published data from a phase 3 trial confirm that cemiplimab improves survival in patients with recurrent cervical cancer, as this indication awaits FDA approval.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news